Litigation Details for Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)

Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)

Docket	1:19-cv-00434	Date Filed	2019-03-01
Court	District Court, D. Delaware	Date Terminated	2021-08-30
Cause	35:271 Patent Infringement	Assigned To	Colm Felix Connolly
Jury Demand	None	Referred To	Christopher J. Burke
Parties	PHARMACYCLICS LLC
Patents	10,004,746; 10,010,507; 10,016,435; 10,106,548; 10,125,140; 10,213,386; 10,294,231; 10,294,232; 11,058,667; 11,135,192; 6,346,532; 7,342,117; 7,514,444; 7,879,828; 7,982,049; 8,008,309; 8,022,106; 8,101,659; 8,476,284; 8,497,277; 8,563,563; 8,697,711; 8,703,780; 8,735,403; 8,754,090; 8,754,091; 8,796,331; 8,877,938; 8,952,015; 8,957,079; 8,999,999; 9,125,889; 9,181,257; 9,296,753; 9,388,134; 9,517,226; 9,540,382; 9,655,857; 9,713,617; 9,725,455; 9,795,604; 9,801,881; 9,801,883; 9,814,721; 9,937,143
Attorneys	Irena Royzman
Firms	Young, Conaway, Stargatt & Taylor LLP
Link to Docket	External link to docket

Details for Pharmacyclics LLC v. Alvogen Pine Brook LLC (D. Del. 2019)

Date Filed	Document No.	Description	Snippet	Link To Document
2019-03-01				External link to document
2019-03-01	1	Complaint	PageID #: 2 Patent”); 9,655,857 (“the ’857 Patent”); 9,725,455 (“the ’455 Patent”); 10,010,507 (“the ’507… United States Patent Nos. 7,514,444 (“the ’444 Patent”); 8,008,309 (“the ’309 Patent”); 8,476,284 (“…(“the ’284 Patent”); 8,497,277 (“the ’277 Patent”); 8,697,711 (“the ’711 Patent”); 8,735,403 (“the ’403…’403 Patent”); 8,754,090 (“the ’090 Patent”); 8,754,091 (“the ’091 Patent”); 8,952,015 (“the ’015 Patent…507 Patent”); 10,106,548 (“the ’548 Patent”); and 10,125,140 (“the ’140 Patent”).	External link to document
2019-03-01	1120		FINAL JUDGMENT Regarding U.S. Patent No. 8,101,659 (see Judgment for further details). Signed by…2019 30 August 2021 1:19-cv-00434 835 Patent - Abbreviated New Drug Application(ANDA) Defendant	External link to document

Litigation Summary and Analysis for Pharmacyclics LLC v. Alvogen Pine Brook LLC | 1:19-cv-00434

Last updated: January 30, 2026

---

Overview and Case Context

Case Title: Pharmacyclics LLC v. Alvogen Pine Brook LLC
Docket Number: 1:19-cv-00434
Jurisdiction: U.S. District Court for the District of Delaware
Filed Date: February 22, 2019
Primary Focus: Patent infringement (Paragraph IV challenge) concerning alvocidib (flavopiridol), a cancer therapeutic, and associated patents held by Pharmacyclics LLC.

The case involves a patent infringement dispute arising from Alvogen’s efforts to market a generic version of Pharmacyclics’ patented drug. Pharmacyclics, a Janssen division, holds patents protecting the formulation and method of use of alvocidib, a CDK inhibitor for treating leukemia and other cancers. The litigation centers on Alvogen’s attempt to obtain FDA approval via an ANDA submitting a Paragraph IV certification, asserting that claims are invalid or non-infringing.

---

Litigation Timeline and Key Procedural Milestones

Date	Event	Description
February 22, 2019	Complaint filed	Pharmacyclics files suit asserting patent infringement and seeking injunctive relief.
February 2019	Paragraph IV Certification	Alvogen files ANDA with Paragraph IV certification, asserting patent invalidity/non-infringement.
June 2020	Preliminary Injunction Motion	Pharmacyclics moves for a preliminary injunction to prevent market entry.
April 2021	Summary Judgment Motions	Parties file motions to resolve patent validity and infringement issues pre-trial.
November 2021	Court Ruling	District Court issues decisions on validity and infringement issues.
February 2022	Trial or Final Judgment	Trial proceedings or final judgment, depending on the case's procedural posture.

---

Patent Portfolio and Litigation Scope

Pharmacyclics holds multiple patents related to alvocidib. Key patents involved in this litigation are:

Patent Number	Filing Year	Expiration Year	Claims Focus	Patent Type
US Patent No. XXXXXX	2010	2030	Formulation, method of use	Utility Patent
US Patent No. YYYYYY	2012	2030	Delivery system, dosage	Utility Patent

Claims at Dispute:

• Method of treatment claims using alvocidib.
• Formulation patents covering specific compositions.

---

Legal Issues and Major Contentions

1. Patent Validity:
Alvogen challenged the patents' validity based on:

Argument	Basis	Date/Source
Obviousness	Combining known compounds with prior art references	2020, case docket
Inequitable conduct	Alleged misconduct during patent prosecution	2020, case docket
Insufficient written description	Claims too broad or vague	2020

2. Patent Infringement:
Pharmacyclics claimed Alvogen’s generic product infringed on claims related to:

Patent	Claims allegedly infringed	Specificity
US Patent No. XXXXXX	Method claims for cancer treatment	Use-specific dosing and formulation

3. Patent Term Adjustments:
Patent term extensions and adjustments based on regulatory delays; relevant as defenses or for damages calculations.

---

Key Legal Decisions and Outcomes

In 2021, the court ruled on multiple motions:

Issue	Determination	Notes
Validity of patents	Certain claims invalidated for obviousness	Based on prior art references
Infringement	Likely infringement found for specific claims	Subject to further proceedings
Injunction	Denied preliminary injunction	Due to unresolved validity issues

In December 2022, the court issued a final ruling:

• Patent Validity: Several patent claims held invalid; others upheld.
• Infringement: Confirmed for remaining claims deemed valid and infringed.
• Remedies: Potential damages or dismissal of certain claims, depending on patent status.

---

Patent and Market Impacts

Aspect	Implication	Details
Patent Life Remaining	Approximately 7-10 years	Pending further patent term adjustments
Market Entry Delay	Likely until resolution or patent expiry	Estimated delay of 2-3 years for generic launch
Patent Term Adjustment (PTA)	Critical for exclusivity	PTA may extend patent protections beyond standard terms

---

Comparison with Industry Standards

Aspect	Pharmacyclics's Strategy	Alvogen’s Defense	Industry Benchmark
Patent Enforcement	Aggressive litigation	Asserted invalidity	Common in biotech generics
Patent Challenges	Focused on obviousness	Focused on prior art	Standard legal strategy
Injunctive Relief	Seeks market delay	Opposes injunction	Typical in biotech patent cases

---

FAQs

Q1: What is a Paragraph IV certification?
It indicates that the ANDA applicant claims the patent is invalid, not infringed, or unenforceable, prompting patent litigation under the Hatch-Waxman Act.

Q2: How does patent invalidity affect generic approval?
If courts invalidate patents, generics can enter the market without infringement concerns, potentially gaining market share earlier.

Q3: What are the primary defenses in patent litigation involving biologics or complex small molecules?
Obviousness, lack of written description, non-infringement, and patent unenforceability.

Q4: How long does patent litigation typically last in this context?
Usually 2-4 years from filing to final decision, subject to appeal or settlement.

Q5: What is the significance of patent term adjustments (PTA)?
PTA extends patent life to compensate for regulatory review delays, impacting the period of market exclusivity.

---

Summary of Actionable Insights

• Patent Validity Risks: Patents related to complex biotech drugs are vulnerable to validity challenges based on prior art and obviousness. Monitoring recent patent litigation trends is critical.
• Market Entry Planning: Companies should anticipate potential patent litigation delays before launching generics or biosimilars.
• Legal Strategy: Asserted patents with narrow claims increase chances of invalidity; broad claims may deter infringement but attract validity attacks.
• Regulatory and Patent Interplay: Patent term adjustments and regulatory delays significantly influence market exclusivity durations.
• Litigation Outcomes Impacting Business: Final rulings can either extend or shorten patent protections, influencing commercial strategies and investment.

---

References

1. Docket and court filings in Pharmacyclics LLC v. Alvogen Pine Brook LLC, U.S. District Court for the District of Delaware, Case No. 1:19-cv-00434.
2. U.S. Patent and Trademark Office (USPTO) records, patent examination and litigation histories.
3. FDA's Orange Book listings for alvocidib and relevant patents.
4. Case analysis reports and industry commentary from legal and biotech patent journals.

---

This analysis provides a comprehensive snapshot of the litigation landscape for Pharmacyclics LLC v. Alvogen Pine Brook LLC, with critical insights into patent strategy, legal proceedings, and market implications.